How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,705 results for

(coronavir* OR betacoronavir* OR wuhan OR 2019ncov OR ncov2019 OR ncov OR #ncov OR #coronavir* OR "Covid 19" OR "SARS CoV 2" Or "sarscov 2" OR "corona virus" OR "corona viruses" OR "new cov" OR "novel cov" OR "nouveau cov" OR COVID19 OR ncov OR ncov2019 OR novel coronavir* OR pandemic* OR sarscov2) from:2020 to:2033

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. [INTERIM ANALYSIS] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Full Text available with Trip Pro

[INTERIM ANALYSIS] Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK CDEI - Oxford-AstraZeneca COVID-19 Vaccine (Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK — CDEI Open Menu Close Menu Open Menu Close Menu Dec 17 Written By Note: Interim (...) CRP = C-reactive protein COVID-19 = coronavirus disease ECMO = extracorporeal membrane oxygenation ECG = electrocardiogram FiO2 = oxygen concentration HR = hazard ratio IQR = interquartile range ITT = intention to treat LOC = level of consciousness MAP = mean arterial pressure n = number of patients PaO2 = partial pressure of oxygen p-value = probability value RR = respiratory rate RT-PCR = reverse transcriptase polymerase chain reaction SaO2 = oxygen saturation SARS-CoV-2 = severe acute

2021 Covid-19 Drug Evidence Initiative

2. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Full Text available with Trip Pro

in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine (MenACWY) as control. Healthy adults aged 18-55 years with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms were randomly assigned (1:1) to receive ChAdOx1 nCoV-19 at a dose of 5 × 1010 viral particles or MenACWY as a single intramuscular injection. A protocol amendment in two of the five sites allowed (...) Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and immunogenicity of a viral vectored coronavirus vaccine that expresses the spike protein of SARS-CoV-2.We did a phase 1/2, single-blind, randomised controlled trial in five trial sites

2020 Lancet

3. COVID-19 - SARS-CoV-2

COVID-19 - SARS-CoV-2 1 Chapter 14a - COVID-19 - SARS-Cov-2 Chapter 14a - COVID-19 - SARS-CoV-2 12 February 2021 14a COVID-19 - SARS-CoV-2 NOTIFIABLE The virus COVID-19 disease first emerged as a presentation of severe respiratory infection in Wuhan, China in late 2019 (WHO, 2020). By January 2020, lower respiratory samples taken from affected patients were sequenced and demonstrated a novel coronavirus (SARS-CoV-2) (Huang et al, 2020). The first two cases in the UK were seen in late January (...) (Lillie et al, 2020). In March 2020, the WHO declared a SARS-CoV-2 pandemic (WHO Director-General, 2020). SARS-CoV-2 is a member of the family of Coronaviridae and genus Betacoronavirus (Zhu et al, 2020). Phylogenetic analysis of SARS-CoV-2 has shown that it is genetically distinct from the SARS coronavirus (Dhama, et al. 2020), but appears to share strong sequence similarity to bat coronaviruses in China (Lam et al, 2020). As with other coronaviruses, SARS-CoV-2 is an RNA virus which encodes four

2021 The Green Book

4. mRNA-1273 SARS-CoV-2 - Moderna Covid-19 vaccine

mRNA-1273 SARS-CoV-2 - Moderna Covid-19 vaccine Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2021 Health Canada - Drug and Health Product Register

5. COVID-19: Do weather conditions influence the transmission of the coronavirus (SARS-CoV-2)?

COVID-19: Do weather conditions influence the transmission of the coronavirus (SARS-CoV-2)? Do weather conditions influence the transmission of the coronavirus (SARS-CoV-2) - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Do weather conditions influence the transmission of the coronavirus (SARS-CoV-2) Jon Brassey, Carl Heneghan, Kamal R. Mahtani, Jeffrey K. Aronson On behalf of the Oxford COVID-19 (...) and the effect of the weather on the host. The weather effect is minimal, and all estimates are subject to significant biases reinforcing the need for robust public health measures. BACKGROUND Most countries across the globe have now implemented a suite of strategies to reduce transmission of the novel coronavirus (2019-nCoV) and mitigate the effects of the COVID-19. The virus is known to have originated in the port city of Wuhan, in the central Hubei province, China. At the time when the first case

2020 Oxford COVID-19 Evidence Service

6. Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. Full Text available with Trip Pro

Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. The year 2020 has seen a major and sustained outbreak of a novel betacoronavirus (severe acute respiratory syndrome (SARS)-coronavirus (CoV)-2) infection that causes fever, severe respiratory illness and pneumonia, a disease called COVID-19. At the time of writing, the death toll was greater than 120 000 worldwide with more than 2 million documented infections. The genome of the CoV encodes a number of structural (...) for vaccine development, blocking therapy with antibodies and diagnostic antigen-based tests. This review briefly outlines the structure and function of the 2019 novel CoV/SARS-CoV-2 spike protein S.© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

2020 Journal of Clinical Pathology

7. The ChAdOx1 nCoV-19 covid-19 vaccine from AstraZeneca: great uncertainty over its efficacy

foreseeable adverse effects of a viral vector vaccine are those common to vaccines in general, notably local reactions at the injection site and systemic reactions. The possibility of the vaccine worsening Sars-CoV-2 infection is a hypothesis that must be taken into account, in view of the findings of certain animal studies with a Sars-CoV-1 coronavirus vaccine (5). Among the 37 patients who developed covid-19 after receiving the ChAdOx1 nCoV-19 vaccine, two were hospitalised and none developed severe (...) : as with the tozinameran vaccine (Comirnaty°, Pfizer/BioNTech), limited data and unanswered questions" 6 January 2021. 7 Voysey M et al. "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK" Lancet 2020: 13 pages. Published online at www.thelancet.com on 8 December 2020. 8 "Phase III double-blind, placebo-controlled study of AZD1222 for the prevention of covid-19 in adults. NCT04516746

2021 Prescrire

8. The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review Full Text available with Trip Pro

, Cardiff, CF10 4PL, United Kingdom Peter Groves 1 Health Technology Wales, Life Sciences Hub, 3 Assembly Square , Cardiff, CF10 4PL, United Kingdom STRUCTURED ABSTRACT Objectives We undertook a rapid systematic review with the aim of identifying evidence that could be used to answer the following research questions: (1) What is the clinical effectiveness of tests that detect the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to inform COVID-19 diagnosis? (2) What (...) The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review | medRxiv Search for this keyword The effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic

2020 Cold Spring Harbor Laboratory

9. The Effectiveness of Tests to Detect the Presence of SARS-CoV-2 Virus, and Antibodies to SARS-CoV-2, to Inform COVID-19 Diagnosis: A Rapid Systematic Review Full Text available with Trip Pro

The Effectiveness of Tests to Detect the Presence of SARS-CoV-2 Virus, and Antibodies to SARS-CoV-2, to Inform COVID-19 Diagnosis: A Rapid Systematic Review The Effectiveness of Tests to Detect the Presence of SARS-CoV-2 Virus, and Antibodies to SARS-CoV-2, to Inform COVID-19 Diagnosis: A Rapid Systematic Review by David Jarrom, Lauren Elston, Jennifer Washington, Matthew Prettyjohns, Kimberley Cann, Susan Myles, Peter Groves :: SSRN Share: Permalink Using these links will ensure access (...) to Detect the Presence of SARS-CoV-2 Virus, and Antibodies to SARS-CoV-2, to Inform COVID-19 Diagnosis: A Rapid Systematic Review 67 Pages Posted: 11 Aug 2020 Health Technology Wales Health Technology Wales Health Technology Wales Health Technology Wales Health Technology Wales Health Technology Wales Health Technology Wales Abstract Background: In response to the emergence of the SARS-CoV-2 virus and the subsequent COVID-19 pandemic, a number of tests have been rapidly developed to assist with COVID-19

2020 SSRN Electronic Journal

10. SARS-CoV-2 viral load and the severity of COVID-19 Full Text available with Trip Pro

SARS-CoV-2 viral load and the severity of COVID-19 SARS-CoV-2 viral load and the severity of COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website SARS-CoV-2 viral load and the severity of COVID-19 March 26, 2020 Carl Heneghan, Jon Brassey, Tom Jefferson Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences University of Oxford (...) The initial dose of virus and the amount of virus an individual has at any one time might worsen the severity of COVID 19 disease. Viral load is a measure of the number of viral particles present in an individual. Higher SARS-CoV-2 viral loads. might worsen outcomes, and data from China suggests the with more severe disease. The amount of virus exposure at the start of infection – the infectious dose – may increase the severity of the illness and is also. linked to a higher viral load Healthcare workers

2020 Oxford COVID-19 Evidence Service

11. Is there any significant difference in sensitivity of COVID-19 virus (SARS-CoV-2) tests based on swabs from oropharyngeal (OP) vs nasopharyngeal (NP) sampling vs both?

recommending collecting only nasopharyngeal swabs (NP), not NP and oropharyngeal swabs (OP). However, OP would be easier to do without training than NP, so one question is whether there is a significant difference in sensitivity between the two methods or using them in combination. SEARCH STRATEGY Search terms: COVID-19, SARS-CoV-2, wuhan coronavirus, 2019-nCoV, 2019nCoV, nasopharyngeal, oropharyngeal, swab, diagnosis, diagnostic, test, sensitivity Databases: PubMed, Embase, Web of Science, Scopus (...) Is there any significant difference in sensitivity of COVID-19 virus (SARS-CoV-2) tests based on swabs from oropharyngeal (OP) vs nasopharyngeal (NP) sampling vs both? Comparative accuracy of oropharyngeal and nasopharyngeal swabs for diagnosis of COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Comparative accuracy of oropharyngeal and nasopharyngeal swabs for diagnosis of COVID-19 March 26

2020 Oxford COVID-19 Evidence Service

12. COVID-19: Spreading SARS-CoV-2 through ocular fluids

COVID-19: Spreading SARS-CoV-2 through ocular fluids Maximising mobility in the elderly when isolated with COVID-19 - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Maximising mobility in the elderly when isolated with COVID-19 JAMIE HARTMANN-BOYCE 20/03/2020 On behalf of the Oxford COVID-19 Evidence Service Team Centre for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences

2020 Oxford COVID-19 Evidence Service

13. Covid-19: Immunity after SARS-CoV-2 infection

Covid-19: Immunity after SARS-CoV-2 infection Immunity after SARS-CoV-2 infection - NIPH Search for: Søk Menu To top level Close Infectious diseases & Vaccines Mental & Physical health Environment & Lifestyle Health in Norway Quality & Knowledge Research & Access to data About NIPH Close Immunity after SARS-CoV-2 infection Order Download: Key message The findings in this memo are based on rapid searches in PubMed, EMBASE and two pre-print databases. One researcher went through all search (...) on the severity of SARS-CoV-2 infection? Seroconversion rate and timing do not appear to differ between patients with mild to severe/critical COVID 19 infection. Studies of asymptomatic cases are however lacking. Can antibodies be transmitted from women infected with SARS-CoV-2 to the fetus via placenta and thus confer immunity in the newborn? Results from one small study suggest that antibodies from SARS-CoV-2 infected women may be transmitted to the foetus during pregnancy, but the evidence is uncertain

2020 Norwegian Institute of Public Health

14. Current epidemiology and guidance for COVID-19 caused by SARS-CoV-2 virus, in children: March 2020

-CoV-2 virus, in children: March 2020 Posted: Mar 25 2020 The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our . Principal author(s) Nicole Le Saux, Canadian Paediatric Society, The emergence in December 2019 of COVID-19, caused by a novel coronavirus, and its subsequent spread around the world, led the World Health Organization to declare a pandemic on March 11, 2020 (...) ):270-4. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med 2020;27(2): DOI:10.1093/jtm/taaa021. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; online ahead of print: DOI:10.1001/jama.2020.3786. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective

2020 Canadian Paediatric Society

15. Covid-19: Contact based transmission of SARS-CoV-2 - a rapid review

. April 2020) Restricted to SARS-CoV-2 and studies published after 1. December 2019. ((((Coronavirus[mh] OR "Coronavirus Infections"[mh] OR "corona virus"[tw] OR coro- navirus*[tw] OR coronovirus*[tw]) AND (novel[tw]OR 2019[tw] OR Wuhan[tw] OR Huanan[tw])) OR "covid-19"[nm] OR "severe acute respiratory syndrome coronavirus 2"[nm] OR "COVID-19"[tw] OR COVID19[tw] OR CORVID-19[tw] OR CORVID19[tw] OR "coronavirus 2"[tw] OR "corona virus 2"[tw] OR nCoV[tw] OR 2019nCoV[tw] OR "SARS-CoV-2"[tw] OR "SARS-CoV2 (...) into cultured cells. In brief, the study showed that SARS-CoV can survive on inanimate surfaces and remain infec- tious for several days. The infectivity of the virus was strongly reduced following heating or UV irradiation (2). In January 2020, Kampf and co-workers reviewed literature about the persistence of coronaviruses (3). The authors included 22 studies. None of the included studies in- vestigated SARS-CoV-2, but data from SARS-CoV, MERS-CoV and other corona- viruses suggests these viruses can

2020 Norwegian Institute of Public Health

16. Rapid Expert Consultation on the Possibility of Bioaerosol Spread of SARS-CoV-2 for the COVID-19 Pandemic

Rapid Expert Consultation on the Possibility of Bioaerosol Spread of SARS-CoV-2 for the COVID-19 Pandemic Rapid Expert Consultation on the Possibility of Bioaerosol Spread of SARS-CoV-2 for the COVID-19 Pandemic (April 1, 2020) | The National Academies Press Menu Menu ( 2020 ) View Cover ( 2020 ) × Embed Book Widget Copy the HTML code below to embed this book in your own blog, website, or application. Custom Size: × × Close What is a prepublication? An uncorrected copy, or prepublication (...) , public health, public health preparedness and response, biological sciences, clinical care and crisis standards of care, risk communication, and regulatory issues. This publication responds to questions concerning the possibility that the SARS-Cov-2 virus could be spread by conversation, in addition to sneeze/cough-induced droplets. Suggested Citation National Research Council. 2020. Rapid Expert Consultation on the Possibility of Bioaerosol Spread of SARS-CoV-2 for the COVID-19 Pandemic (April 1

2020 Covid-19 Ad hoc papers

17. Rapid Expert Consultation on SARS-CoV-2 Survival and Incubation for the COVID-19 Pandemic

Rapid Expert Consultation on SARS-CoV-2 Survival and Incubation for the COVID-19 Pandemic Rapid Expert Consultation Update on SARS-CoV-2 Surface Stability and Incubation for the COVID-19 Pandemic (March 27, 2020) | The National Academies Press Menu Menu ( 2020 ) View Cover ( 2020 ) × Embed Book Widget Copy the HTML code below to embed this book in your own blog, website, or application. Custom Size: × × Close What is a prepublication? An uncorrected copy, or prepublication, is an uncorrected (...) Citation National Academies of Sciences, Engineering, and Medicine. 2020. Rapid Expert Consultation Update on SARS-CoV-2 Surface Stability and Incubation for the COVID-19 Pandemic (March 27, 2020) . Washington, DC: The National Academies Press. https://doi.org/10.17226/25763. Import this citation to: Publication Info 10 pages | 8.5 x 11 DOI: Contents Search Inside This Book SEARCH Table of Contents skim chapter 1-10 Rights Copyright Information The National Academies Press and the Transportation

2020 Covid-19 Ad hoc papers

18. Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review Full Text available with Trip Pro

effectiveness of tests that detect the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to inform COVID-19 diagnosis? (2) What is the clinical effectiveness of tests that detect the presence of antibodies to the SARS-CoV-2 virus to inform COVID-19 diagnosis? Design and setting: Systematic review and meta-analysis of studies of diagnostic test accuracy. We systematically searched for all published evidence on the effectiveness of tests for the presence of SARS-CoV-2 virus (...) Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features

2020 EvidenceUpdates

19. Canadian Thoracic Society recommendations regarding the use of face masks by the public during the SARS-CoV-2 (COVID-19) pandemic

Canadian Thoracic Society recommendations regarding the use of face masks by the public during the SARS-CoV-2 (COVID-19) pandemic 1 ‘In Press’. Submitted for publication in the CJRCCSM on June 2, 2020. Canadian Thoracic Society recommendations regarding the use of face masks by the public during the SARS-CoV-2 (COVID-19) pandemic Mohit Bhutani a , Paul Hernandez b , Connie Yang c , Jean Bourbeau d , Christopher Licskai e , Gail Dechman f , Anne Van Dam g , Samir Gupta h a Department of Medicine (...) is a rapidly evolving situation and recommendations may change as the science informs us. We recommend to routinely visit our COVID-19 website for updates at https://cts-sct.ca/covid-19. 2 ‘In Press’. Submitted for publication in the CJRCCSM on June 2, 2020. Background As Canada begins to relax the measures instituted to limit the spread of the SARS-CoV-2 virus, recommendations by the Public Health Agency of Canada and local public health authorities are simultaneously evolving to assist in this process

2020 Canadian Thoracic Society

20. Heart Rhythm Journal Review: SARS-CoV-2, COVID-19 & Inherited Arrhythmia Syndromes

Heart Rhythm Journal Review: SARS-CoV-2, COVID-19 & Inherited Arrhythmia Syndromes Heart Rhythm Journal Review: SARS-CoV-2, COVID-19 & Inherited Arrhythmia Syndromes | Heart Rhythm Society Utility Menu Main navigation Search Leave this field blank Main Menu Breadcrumb ,” recently published in Heart Rhythm by Cheng-I. Wu, MD, and colleagues, the authors describe the potential COVID-19 associated risks and therapeutic considerations for patients with distinct inherited arrhythmia syndromes

2020 Heart Rhythm Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>